[go: up one dir, main page]

WO2000067766A1 - Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina - Google Patents

Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina Download PDF

Info

Publication number
WO2000067766A1
WO2000067766A1 PCT/RU1999/000480 RU9900480W WO0067766A1 WO 2000067766 A1 WO2000067766 A1 WO 2000067766A1 RU 9900480 W RU9900480 W RU 9900480W WO 0067766 A1 WO0067766 A1 WO 0067766A1
Authority
WO
WIPO (PCT)
Prior art keywords
πρedelaχ
πρeπaρaτa
venom
οτnοsheniyu
vybiρayuτ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU1999/000480
Other languages
English (en)
Russian (ru)
Inventor
Larisa Vasilievna Dubinina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU30858/00A priority Critical patent/AU3085800A/en
Publication of WO2000067766A1 publication Critical patent/WO2000067766A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

  • the invention is subject to the field of medicine and may be used, for example, in the case of a pharmaceutical-regenerative drug, and the treatment of using it
  • Reactive-regenerative drugs are known that contain active components on basic active components and omnipotent components [1].
  • the product has been found to be biologically active, which contains biologically active substances that are harmful to the body.
  • Izves ⁇ en s ⁇ s ⁇ b izg ⁇ vleniya ⁇ e ⁇ a ⁇ a ⁇ ivn ⁇ - ⁇ egene ⁇ a ⁇ ivn ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a, v ⁇ lyuchayuschy ⁇ dg ⁇ v ⁇ u is ⁇ dny ⁇ ⁇ m ⁇ nen ⁇ v, i ⁇ vzaim ⁇ svyazyvanie with ⁇ m ⁇ schyu ⁇ as ⁇ v ⁇ i ⁇ elya and d ⁇ ugi ⁇ ⁇ m ⁇ nen ⁇ v, and ⁇ chis ⁇ u ⁇ es ⁇ i ⁇ vanie g ⁇ v ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a [1].
  • Izves ⁇ en s ⁇ s ⁇ b izg ⁇ vleniya ⁇ e ⁇ a ⁇ a ⁇ ivn ⁇ - ⁇ egene ⁇ a ⁇ ivn ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a, v ⁇ lyuchayuschy ⁇ dg ⁇ v ⁇ u is ⁇ dny ⁇ ⁇ m ⁇ nen ⁇ v, i ⁇ vzaim ⁇ svyazyvanie with ⁇ m ⁇ schyu ⁇ as ⁇ v ⁇ i ⁇ elya, and emulga ⁇ a ⁇ nse ⁇ van ⁇ a, and ⁇ chis ⁇ u ⁇ es ⁇ i ⁇ vanie g ⁇ v ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a [3] - ⁇ i ⁇ .
  • Distinctive features of the method are included in that, as a part of the accessory, an empty anesthetics is removed.
  • the distributor - distilled water in the process of its preparation reduces the cost of salted acid, thereby avoiding the concentration of saline acid. They mix the prepared components and homogenize the mixture, achieving a total volume of 0.3 ml of non-mixed components, the components are mixed. For a volume of 5 ml of the whole mixture.
  • the distributor - distilled water in the process of its preparation acidifies the saline acid. Ensuring the concentration of saline acid is equal to 1%. Mix the prepared components and homogenize the mixture, achieving a total volume of 0.2 ml of non-homogenized mixture of 5 ml of the mixture.
  • the distributor - distilled water in the process of its preparation reduces the cost of salted acid, thereby avoiding the concentration of saline acid.
  • Example 1 Patient G. 46 years old weighing 104 kg. Diagnosis: interstitial disease (herniation 4-5 calls), compression of the cerebral cortex at this level, which is growing at an accident.
  • drugs For the treatment of drugs, they are administered cyclically in 17 stages with a total of 62 injections. For each of these stages, 4–6 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
  • the injection area is selected in this case as equal to 4 cm 2 for an area of 24 cm for a large patient’s area of 0.5 patient.
  • For treatment they use a total of 14.5 mg of the drug.
  • anesthetics an equal of 10 mg is taken and ⁇ is equal to 0.8.
  • Example 2 Patient P. 33 years old weighing 80 kg. Diagnosis: atrial perennial, simple auto-herniation of intervertebral disc with a size of 13 mm, expressed by acute pain syndrome.
  • drugs they are administered cyclically in 25 stages with a total of 100 injections. For each of these steps, 4–8 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
  • the injection area is selected in this example as equal to 6 cm 2 for the area of 6 cm 2 for a large patient’s body at a rate of 0.6.
  • 18.3 mg of the drug is used in its entirety. With this dose of anesthetics, an equal of 15 mg is taken.
  • Example 3 Bolnoy ⁇ . 40 years old weighing 92 kg. Diagnosis: hernia 4-5 intercostal disc with a size of 17 mm, expressed by acute pain syndrome. For treatment eleven
  • the drugs are administered cyclically in 25 stages with a total of 100 injections. For each of these stages, 4–8 injections are given. Injections are administered internally to a depth of 4 mm, and when administered to a depth of 6 mm, the maximum injection depth is 13 mm.
  • the injection area is selected in this case as equal to 6 cm for the area of 6 cm for the patient's body at a pressure of 0.6.
  • For treatment they use the whole final dose of 20.4 mg of the drug. With this dose of anesthetics, an equal of 17 mg is taken.
  • ⁇ izhnie and ve ⁇ nie values were zayavlenny ⁇ ⁇ edel ⁇ v ⁇ lucheny on ⁇ sn ⁇ ve s ⁇ a ⁇ is ⁇ iches ⁇ y ⁇ b ⁇ ab ⁇ i ⁇ ezul ⁇ a ⁇ v e ⁇ s ⁇ e ⁇ imen ⁇ alny ⁇ issled ⁇ vany, analysis and ⁇ b ⁇ bscheniya i ⁇ and izves ⁇ ny ⁇ of ⁇ ubli ⁇ vanny ⁇ is ⁇ chni ⁇ v readyy ⁇ , is ⁇ dya of usl ⁇ viya d ⁇ s ⁇ izheniya u ⁇ azann ⁇ g ⁇ ⁇ e ⁇ niches ⁇ g ⁇ ⁇ ezul ⁇ a ⁇ a and is ⁇ lz ⁇ vaniem ⁇ a ⁇ a iz ⁇ b ⁇ e ⁇ a ⁇ els ⁇ y in ⁇ uitsii.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention se rapporte au domaine de la médecine et notamment au traitement de troubles du système locomoteur tels que l'ostéochondrose, la radiculite, la radiculonévrite, l'arthrite et l'arthrose. Cette invention concerne une préparation réparatrice et régénératrice qui comprend un composant bioactif à base d'un poison animal, un solvant, un émulsifiant, un conservateur ainsi que des impuretés de ballastage tolérées. Le poison consiste en du venin provenant essentiellement de vipère commune (vipera berus berus). Le procédé de fabrication de cette préparation réparatrice et régénératrice consiste à préparer les composants de départ, à les lier à l'aide du solvant, de l'émulsifiant et du conservateur, puis à purifier et à tester le produit fini. La lyophilisation et la cristallisation du venin de vipère commune se font en maintenant, dans un local industriel, une température T1 qui se situe dans la plage 1,9 ≤ (zT1+T2)/T2 ≤ 2,1 (température en degrés K) où z représente un coefficient expérimental choisi en fonction de la saison de prélèvement du venin et de la teneur en humidité de celui-ci, et se situe dans la plage 0,28 ≤ z ≤ 1,6. Cette invention concerne également un procédé d'utilisation thérapeutique de cette préparation réparatrice et régénératrice.
PCT/RU1999/000480 1999-05-05 1999-12-10 Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina Ceased WO2000067766A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30858/00A AU3085800A (en) 1999-05-05 1999-12-10 Restorative and regenerative preparation, method for producing the same and therapeutical use according to l.v. dubinina

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU99108706A RU2146146C1 (ru) 1999-05-05 1999-05-05 Репаративно-регенеративный препарат, способ его изготовления и лечебного использования по л.в.дубининой
RU99108706 1999-05-05

Publications (1)

Publication Number Publication Date
WO2000067766A1 true WO2000067766A1 (fr) 2000-11-16

Family

ID=20219074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1999/000480 Ceased WO2000067766A1 (fr) 1999-05-05 1999-12-10 Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina

Country Status (3)

Country Link
AU (1) AU3085800A (fr)
RU (1) RU2146146C1 (fr)
WO (1) WO2000067766A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261719C2 (ru) * 2000-10-27 2005-10-10 Писарев Александр Геннадьевич Водно-спиртовая настойка
WO2003075936A1 (fr) * 2002-03-11 2003-09-18 Nina Alexandrovna Karagoujova Procede d'elevage des serpents pour obtenir des composants de poison
RU2266746C2 (ru) * 2004-03-12 2005-12-27 Закрытое Акционерное Общество "Лорр" Средство для лечения невралгических заболеваний
RU2276987C2 (ru) * 2004-03-30 2006-05-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Способ иммунобиохимической коррекции организма крупного рогатого скота
RU2355407C1 (ru) * 2008-01-09 2009-05-20 Юрий Антонович Кошелев Средство для профилактики и лечения заболеваний опорно-двигательного аппарата

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126676A (en) * 1977-07-22 1978-11-21 Sanders Murray J Modified neurotoxin derived from naja genus snake venom
RU2093160C1 (ru) * 1991-07-24 1997-10-20 Бейреш Экспорт-Импорт РТ Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания
RU2106863C1 (ru) * 1996-12-27 1998-03-20 Лариса Васильевна Дубинина Способ лечения заболеваний опорно-двигательного аппарата и периферической нервной системы по л.в.дубининой

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888977A (en) * 1973-02-01 1975-06-10 Murray J Sanders Modified neurotoxin
RU2088216C1 (ru) * 1994-07-04 1997-08-27 Саратовский научно-исследовательский институт травматологии и ортопедии Средство для лечения ревматоидного артрита

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126676A (en) * 1977-07-22 1978-11-21 Sanders Murray J Modified neurotoxin derived from naja genus snake venom
GB2001244A (en) * 1977-07-22 1979-01-31 Sanders M Neurotoxin derived from naja genus snake venom
RU2093160C1 (ru) * 1991-07-24 1997-10-20 Бейреш Экспорт-Импорт РТ Фармацевтическая композиция и способ воздействия на ретикулоэндотелиальную систему, лечения муковисцидоза и хронических болевых синдромов, сопровождающих заболевания опорно-двигательного аппарата и онкологические заболевания
RU2106863C1 (ru) * 1996-12-27 1998-03-20 Лариса Васильевна Дубинина Способ лечения заболеваний опорно-двигательного аппарата и периферической нервной системы по л.в.дубининой

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASHKOVSKY M.D.: "Lekarstevennye sredstva m.", MEDITSINA, 1993, pages 415 - 416 *

Also Published As

Publication number Publication date
RU2146146C1 (ru) 2000-03-10
AU3085800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
CN1120458A (zh) 生理活性肽组合物
TW200911279A (en) Compositions, uses, and method of making wound care products from naturally occurring food ingredients
RU2112504C1 (ru) Средство для лечения заболеваний предстательной железы "витапрост"
RU2200564C1 (ru) Лекарственная форма пантогематогена на гелевой основе
EA000885B1 (ru) Лекарственное средство и способ медикаментозного воздействия на организм
RU2036651C1 (ru) Биогенный стимулятор для лечения и профилактики заболеваний сельскохозяйственных животных
JP7391204B2 (ja) ワモンゴキブリの抽出物、製剤、調製方法およびその使用
WO2000067766A1 (fr) Preparation reparatrice et regeneratrice, procede de fabrication et utilisation therapeutique selon l.v. doubinina
CN111569044B (zh) 一种含紫球藻多肽的组合物及其制备方法
WO1994028153A2 (fr) Adn de faible masse moleculaire tiree de laitance d'esturgeon, procede d'obtention de l'adn et preparation pharmaceutique a base de celui-ci
RU2126682C1 (ru) Получаемый из торфа биоактивный продукт, способ его получения и фармацевтические и косметические композиции
CN117051067A (zh) 一种鹿茸活性多肽组合物及其制备方法
RU2070409C1 (ru) Препарат для лечения мастита у лактирующих животных
RU2350342C1 (ru) Способ изготовления геля на основе водного экстракта из пантов
Bartholow A practical treatise on materia medica and therapeutics
US4323496A (en) Innoxious interferon-inducing substance, inducing agent and process for producing same
RU2110272C1 (ru) Средство для лечения термических поражений кожи, трофических язв, пролежней и длительно незаживающих ран
CN107596355A (zh) 一种医用镇痛、消肿、退热的外用凝胶剂及其制备方法
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
WO1992006696A1 (fr) Procede d'obtention d'une preparation bioactive a partir du sang
RU2089197C1 (ru) Препарат пролонгированного действия и способ его получения
CN112353997A (zh) 一种可吸收胶原蛋白海绵制备方法及应用
RU2074727C1 (ru) Способ лечения и профилактики желудочно-кишечных заболеваний телят и поросят
CN113501869A (zh) 具有创面修复作用的肽
HUP0301119A2 (hu) Bioaktiváló hatóanyag és gyógyszerkészítmény

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase